Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.8 million.

  • Ovid Therapeutics' Free Cash Flow rose 1453.32% to -$12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.0 million, marking a year-over-year increase of 3452.26%. This contributed to the annual value of -$56.1 million for FY2024, which is 2225.9% down from last year.
  • As of Q3 2025, Ovid Therapeutics' Free Cash Flow stood at -$12.8 million, which was up 1453.32% from -$4.8 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Free Cash Flow peaked at $160.9 million during Q1 2021, and registered a low of -$20.1 million during Q1 2022.
  • Its 5-year average for Free Cash Flow is -$3.6 million, with a median of -$12.1 million in 2023.
  • Over the last 5 years, Ovid Therapeutics' Free Cash Flow had its largest YoY gain of 96496.04% in 2021, and its largest YoY loss of 62918.48% in 2021.
  • Over the past 5 years, Ovid Therapeutics' Free Cash Flow (Quarter) stood at -$12.2 million in 2021, then rose by 23.56% to -$9.3 million in 2022, then fell by 28.0% to -$11.9 million in 2023, then grew by 15.73% to -$10.0 million in 2024, then dropped by 27.93% to -$12.8 million in 2025.
  • Its Free Cash Flow was -$12.8 million in Q3 2025, compared to -$4.8 million in Q2 2025 and -$10.3 million in Q1 2025.